Show simple item record

dc.contributor.advisorTryland, Morten
dc.contributor.advisorRomano, Javier
dc.contributor.advisorLarsen, Anett
dc.contributor.authorMagnuson, Emily Elizabeth
dc.date.accessioned2019-11-15T10:09:51Z
dc.date.available2019-11-15T10:09:51Z
dc.date.issued2018-11-15
dc.description.abstractCervid herpesvirus 2 (CvHV2) is an alphaherpesvirus found in Rangifer subspecies throughout most of the circumpolar Arctic and the causative agent of infectious keratoconjunctivitis (IKC) in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus). IKC occurs as regular outbreaks, affecting dozens of reindeer in a herd, and is most common and severe among calves and young animals. IKC often appears as mild clinical signs from which the animals often recover, but the disease can progress to more advanced stages where the eye is severely damaged, resulting in blindness or death. Development of an antiviral therapy for CvHV2 could improve animal welfare conditions and reduce economic losses within reindeer herding industry in Fennoscandia. To our knowledge, only one pilot study has previously tested the effectiveness of antiviral drugs against CvHV2 and indicated that the nucleoside analog drug Acyclovir, commonly used as an antiherpetic treatment in humans and other species, was not successful inhibiting viral replication. This master’s study aimed to further investigate the effect of antiviral drugs against CvHV2 by testing Ganciclovir and Cidofovir, and to evaluate their potential use as part of a treatment for IKC in semi-domesticated reindeer in Fennoscandia. An in vitro experiment which used Madin-Darby bovine kidney (MDBK) cell cultures was used as a preliminary model for natural CvHV2 infection in reindeer. A negative dose-response relationship was found for both Ganciclovir and Cidofovir, however, neither drug was able to completely inhibit the viral replication even at the highest drug concentrations and lowest viral titers tested. These findings indicate that both drugs are tentative candidates for the development of an antiviral treatment for CvHV2, but further studies to attempt to increase the therapeutic index of either drug should be strongly considered before testing in live animals.en_US
dc.identifier.urihttps://hdl.handle.net/10037/16670
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2018 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)en_US
dc.subject.courseIDBIO-3950
dc.subjectBiological Scienceen_US
dc.subjectVDP::Mathematics and natural science: 400::Basic biosciences: 470::General microbiology: 472en_US
dc.subjectVDP::Matematikk og Naturvitenskap: 400::Basale biofag: 470::Generell mikrobiologi: 472en_US
dc.titleEffect of Antiviral Drugs against Cervid Herpesvirus 2 (CvHV2) in vitroen_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)